Misoprostol therapeutics revisited

Pharmacotherapy

Volumn 21, Issue 1, 2001, Pages 60-73

  Davies, N M ^a   Longstreth, J ^a   Jamali, F ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; MISOPROSTOL; PROSTAGLANDIN E1;

DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; FOOD DRUG INTERACTION; GASTRODUODENAL ULCER; GENE EXPRESSION REGULATION; LEUKOCYTE ADHERENCE INHIBITION; RACEMIC MIXTURE; REVIEW; STEREOISOMERISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; HUMANS; MISOPROSTOL; STOMACH ULCER;

EID: 0035161069     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.1.60.34442     Document Type: Review

References (197)

1. Arthrotec: The evidence speaks for itself
2. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion
3. Methotrexate and misoprostol for early abortion in adolescent women
4. Gross and histologic effects of topical misoprostol on canine gastric mucosa
5. Misoprostol preclinical pharmacology
6. Misoprostol in preventing aspirin-induced upper gastrointestinal lesion from bid and tid dosing to controlled release
7. A comparison of misoprostol 400 mcg controlled release bid and misoprostol 200 mcg qid release with placebo in preventing aspirin-induced upper gastrointestinal lesion
8. Antisecretory activity of misoprostol, its racemates, stereoisomers and metabolites in isolated parietal cells
9. Prostaglandins inhibit inflammatory mediator release from rat mast cells
10. Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate
11. Effect of nonsteroidal anti-inflammatory drugs on LFA-1 and ICAM-1 expression in gastric mucosa
12. Effects of the prostaglandin analogue misoprostol on inflammatory mediator release by human monocytes
13. Potential use of prostaglandin E1 analog for cardiovascular disease
14. Tumor necrosis factor and alcoholic liver disease
15. Contrasting effects of misoprostol on systemic and intrapulmonary lipopolysaccharide-induced tumor necrosis factor-alpha
16. The prostaglandin analogs, misoprostol and SC-46275, potently inhibit cytokine release from activated human monocytes
17. The prostaglandin E1 analogue, misoprostol, regulates inflammatory cytokines and immune functions in vitro like the natural prostaglandins E1, E2 and E3
18. Migration of neutrophils from blood to tissue: Alteration of modulatory effects of prostanoid on superoxide generation in rabbits and humans
19. Polymeric delivery of the active isomer of misoprostol reduces systemic availability and uterotonic activity
20. Polymer delivery of the active isomer of misoprostol: A solution to the intestinal side effect problem
21. Effect of salicylic acid on the plasma protein binding and pharmacokinetics of acid
22. Metabolism and pharmacokinetic studies of misoprostol
23. Antiulcer prostaglandin misoprostol single and multiple dose pharmacokinetic profile
24. Effects of food and antacid on oral absorption of misoprostol, a synthetic prostaglandin E1 analog
25. Pharmacokinetics of misoprostol in the elderly, in patients with renal failure and when coadministered with NSAID or antipyrine, propranolol or diazepam
26. Pharmacokinetics of diclofenac and misoprostol when administered alone or as a combination product
27. Effects of misoprostol on the pharmacokinetics of indomethacin in human volunteers
28. Effects of misoprostol or ranitidine on ibuprofen pharmacokinetics
29. Potential drug interactions with misoprostol: Effects on the pharmacokinetics of antipyrine and propranolol
30. Effect of orally administered misoprostol and cimetidine on the steady state pharmacokinetics of diazepam and nordiazepam in human volunteers
31. Misoprostol does not alter the pharmacokinetics of propranolol
32. Interaction entre le misoprostol et l'acenocoumarol
33. Disposition of misoprostol and its active metabolite in patients with normal and impaired renal function
34. Prostaglandins protect kidneys against ischemic and toxic injury by a cellular effect
35. Effects of misoprostol on renal function and plasma enothelin-1 levels during early postoperative stage of living donor renal transplant recipients
36. Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone
37. Inhaled misoprostol blocks guinea pig antigen-induced bronchoconstriction and airway inflammation
38. Effect of misoprostol, a synthetic equivalent of prostaglandin E1, on bronchodilation in bronchial spasm
39. Misoprostol has no favorable effect on bronchial hyperresponsiveness in mild asthmatics
40. The effect of oral prostaglandin E1 on airway responsiveness in asthmatic subjects
41. The influence of misoprostol (synthetic analogue of prostaglandin E1) on aspirin-induced bronchoconstriction in aspirin-sensitive asthma
42. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma
43. A six-week double-blind, placebo controlled, crossover study of the effect of misoprostol in the treatment of aspirin sensitive asthma
44. Misoprostol (Cytotec) in the treatment of peripheral ischaemic disease
45. Treatment of peripheral vascular disease with misoprostol (Cytotec): A pilot study
46. Periodontal repair in dogs: Histologic observations of guided tissue regeneration with a prostaglandin E1 analog/methacrylate composite
47. The immunosuppressive properties of new oral prostaglandin E1 analogs
48. Evaluation of the effects of misoprostol on immunologic competence in normal volunteers
49. Effect of prostaglandin E on immune function in normal healthy volunteers
50. Immune modifying effects of misoprostol and natural prostaglandins
51. In vitro assessment of triple-therapy immunosuppression and prostaglandin analogues enisoprost and misoprostol
52. Prostanoid receptors involved in the relaxation of human bronchial preparations
53. The effects of E series prostaglandins on blastogenic responses in vitro and graft vs. host responses in vivo
54. Effect of prostaglandin PGE1 on blood and tissue lipids in rabbit experimental arteriosclerosis
55. Effects of misoprostol on circulating HDL-cholesterol, total cholesterol, triglycerides and their relationship with hepatic microsomal function
56. Effects of misoprostol on human circulation
57. Effects of an oral prostaglandin E1 agonist on blood pressure and its determinants in essential hypertension
58. Acute effects of misoprostol on digital circulation in patients with Raynaud's phenomenon
59. Immunosuppressive effect of misoprostol: A new synthetic prostaglandin E1 analogue
60. The effect of the prostaglandin analogues misoprostol and enisoprost on the synergy between donor-specific transfusion and cyclosporine in allograft survival
61. Effect of misoprostol on myocardial contractility in rats treated with cyclosporin A
62. The effect of acetaminophen, ibuprofen, and misoprostol on prostaglandin E2 synthesis and the degree and rate of orthodontic tooth movement
63. Protection from radiation-induced oral mucositis by a mouth rinse containing the prostaglandin E1 analog, misoprostol: A placebo controlled double blind clinical trial
64. Bone prophylaxis for high-dose chemotherapy-induced mucositis: A randomized double-blind study
65. The interaction of cytokines, NSAIDs and prostaglandins in cartilage destruction and repair
66. Cartilage maintenance in osteoarthritis: Interaction of cytokines, NSAID and prostaglandins in articular cartilage damage and repair
67. Effects of misoprostol and prostaglandin E2 on proteoglycan biosynthesis and loss in unloaded and loaded articular cartilage explants
68. Misoprostol does not protect articular cartilage from salicylate-induced suppression of proteoglycan synthesis
69. In vitro suppression of transforming growth factor-beta induced stimulation of glycosaminoglycan synthesis by acetylsalicylic acid and its reversal by misoprostol
70. The reduced expression of glucocorticoid receptors in synovial cells induced by nonsteroidal antiinflammatory drugs can be reversed by prostaglandin E1 analog
71. Costimulatory effects of misoprostol and diclofenac on glycosaminoglycan synthesis in human cartilage explants and their therapeutic relevance
72. Effect of misoprostol on acute and chronic inflammation
73. Effect of misoprostol on concentrations of prostaglandins in synovial fluid
74. Misoprostol, a prostaglandin E1 analogue, inhibits basic calcium phosphate crystal-induced mitogenesis and collagenase accumulation in human fibroblasts
75. Effects of misoprostol on bone loss in ovariectomized rats
76. Misoprostol with cyclosporin A prolongs corneal allograft survival in an animal model
77. The role of prostaglandins E2 and F2 alpha in ultraviolet radiation-induced cortical cataracts in vivo
78. The analgesic interaction of misoprostol with nonsteroidal anti-inflammatory drugs
79. Misoprostol-diclofenac interaction study
80. Misoprostol stimulates leukocyte cyclic adenosine 3′, 5′ monophosphate production and synergizes with colchicine: Novel combination of established drugs may boost anti-inflammatory potential
81. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue
82. Involvement of prostaglandins in the down-regulation of allergic plasma leakage observed in rats undergoing pleural eosinophilia
83. Cyclooxygenase-2-derived prostaglandin E2 and lipoxin A4 accelerate resolution of allergic edema in angiostrongylus costaricensis-infected rats: Relationship with concurrent eosinophilia
84. Selective inhibition of the cutaneous late but not immediate allergic response to antigens by misoprostol, a PGE analog. Results of a double-blind, placebo-controlled randomized study
85. Prostaglandin synthesis by the cochlea
86. Synthetic prostaglandin E1 misoprostol as a treatment for tinnitus
87. Idiopathic esophageal ulceration in acquired immuno-deficiency syndrome: Successful treatment with misoprostol and viscous lidocaine
88. Duodenal pH in cystic fibrosis and its relationship to fat malabsorption
89. Effect of misoprostol on fat malabsorption in cystic fibrosis
90. Placebo-controlled trial of misoprostol in cystic fibrosis
91. The use of a synthetic prostaglandin E1 analogue (misoprostol) as an adjunct to pancreatic enzyme replacement in cystic fibrosis
92. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications
93. Cyclooxygenase inhibitors increase Na-K-2Cl cotransporter abundance in thick ascending limb of Henle's loop
94. Renal effects of oral prostaglandin supplementation after ibuprofen in diabetic subjects: A double-blind, placebo-controlled, multicenter trial
95. Evaluation of the renal protective effect of misoprostol in elderly, osteoarthritic patients at risk for nonsteroidal anti-inflammatory drug-induced renal dysfunction
96. No effect of misoprostol on renal function of rheumatoid patients treated with diclofenac
97. Effects of indomethacin and misoprostol on renal function in healthy volunteers
98. Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients
99. Minimization of indomethacin-induced reduction in renal function by misoprostol
100. Evaluation of misoprostol cytoprotection of the bladder with cyclophosphamide (Cytoxan) therapy
101. Clinical response to an oral prostaglandin analogue in patients with interstitial cystitis
102. Effects of a prostaglandin E1 analogue, misoprostol, on renal function in dogs receiving nephrotoxic doses of gentamicin
103. Effects of the prostaglandin E1 analog misoprostol on cyclosporine nephrotoxicity
104. The prostaglandin E1 analog misoprostol reverses acute cyclosporine nephrotoxicity
105. The effect of prostaglandin E1 analog misoprostol on chronic cyclosporine nephrotoxicity
106. Evidence that the risks of misoprostol outweigh its benefits in stable cyclosporine-treated renal allograft recipients
107. Lack of a renal-protective effect of misoprostol in rheumatoid arthritis patients receiving cyclosporin A. Results of a randomized, placebo-controlled trial
108. Cyclosporine nephrotoxicity in rheumatoid arthritis: No effect of short term treatment
109. Misoprostol in renal transplantation
110. Misoprostol in renal transplant recipients: A prospective, randomized, controlled study on the prevention of acute rejection episodes and cyclosporin A nephrotoxicity
111. Randomized trial of misoprostol in patients with chronic renal transplant rejection
112. The dose dependent effect of misoprostol on indomethacin-induced renal dysfunction in well compensated cirrhosis
113. Effects of oral prostaglandins on indomethacin-induced renal failure in patients with cirrhosis and ascites
114. Reversal of hepatorenal syndrome in four patients by peroral (prostaglandin E1 analogue) and albumin administration
115. Reversión de un sindrome hepatorenal con misoprostol oral. Es la dosis la clavede la respuesta?
116. The dose-dependent effect of misoprostol on indomethacin-induced renal dysfunction in well-compensated cirrhosis
117. The effect of misoprostol on indomethacin-induced renal dysfunction in well-compensated cirrhosis
118. Dose-dependent effects of oral misoprostol on renal function in alcoholic cirrhosis
119. Oral or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure
120. The effects of chronic administration of indomethacin and misoprostol on renal function in cirrhotic patients with and without ascites
121. Prostaglandins and the treatment of hepatorenal syndrome in cirrhosis
122. Paradoxical exacerbation of leukocyte-mediated glomerulonephritis with cyclooxygenase inhibition
123. Misoprostol-associated autonomic dyreflexia in a traumatic tetraplegic patient
124. The effects of short-term treatment with the prostaglandin E1 (PGE1) analog on inflammatory mediator production in murine lupus nephritis
125. Gastroduodenal mucosal injury during hepatic arterial infusion of chemotherapeutic agents. Lack of cytoprotection by prostaglandin E1 analogue
126. Misoprostol and omeprazole in the prevention of chemotherapy-induced acute gastroduodenal mucosal injury. A randomized, placebo-controlled pilot study
127. Functional and morphological alterations after irradiation of isolated rat stomach: A model for estimation of radiation injury
128. Time-related interference of misoprostol with experimental gastric cancer formation induced by N-methyl-N′-nitro-N-nitrosoguanidine in the rat
129. Role of prostaglandins in the early phases of experimental gastric carcinogenesis in the rat
130. Improvement of intestinal metaplasia six months after misoprostol treatment
131. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability
132. Short report: The effect of misoprostol on the anaemia of NSAID enteropathy
133. High prevalence of NSAID enteropathy as shown by a simple faecal test
134. Misoprostol is effective treatment for patients with severe chronic constipation
135. Misoprostol in the treatment of chronic refractory constipation: Results of a long-term open label trial
136. The effect of misoprostol on colon cancer
137. Comparison of in vivo intestinal radiation protection by E-prostaglandins
138. Misoprostol in the intestinal lumen protects against radiation injury of the mucosa of the small bowel
139. Radiation protection of the murine intestine by misoprostol, a prostaglandin E1 analogue, given alone or with WR-2721, is stereospecific
140. Misoprostol, a PGE1 analog, protects mice from fission-neutron injury
141. Mucosal protective activity of prostaglandin analogs in rodent colonic inflammation
142. Misoprostol provides a colonic mucosal protective effect during acetic acid-induced colitis in rats
143. Verapamil alters eicosanoid synthesis and accelerates healing during experimental colitis in rats
144. Fish oil-enriched diet is mucosal protective against acetic acid-induced colitis in rats
145. Misoprostol therapy after trinitrobenzene sulfonic acid-induced colitis accelerates healing
146. Attenuation of epithelial injury in acute experimental colitis by immunomodulators
147. Misoprostol accelerates colonic mucosal repair in acetic acid-induced colitis
148. Misoprostol attenuates acetic acid-induced increases in mucosal permeability and inflammation: Role of blood flow
149. Effects of the H2-antagonists famotidine and nizatidine and the cytoprotectant misoprostol on human colonic and rat peritoneal mast cells
150. Influence of misoprostol, a synthetic prostaglandin E1 analog, on the healing of colonic anastomoses in rats
151. Nonsteroidal anti-inflammatory drug-induced colitis and misoprostol
152. Morphological consequences of bisacodyl on normal human rectal mucosa: Effect of a prostaglandin E1 analog on mucosal injury
153. Profuse diarrhea after misoprostol use in a patient with history of Crohn's disease
154. Life-threatening diarrhea after short-term misoprostol use in a patient with Crohn's ileocolitis
155. Diarrhea after misoprostol in Crohn's disease
156. Effect of indomethacin and misoprostol on fasted gallbladder volume and meal-induced gallbladder contractility in humans
157. Misoprostol protection against acetaminophen-induced hepatotoxicity in the rat
158. Acetaminophen-induced microvascular injury in the rat liver: Protection with misoprostol
159. The effect of the prostaglandin analogue misoprostol on rat liver mitochondria after chronic alcohol feeding
160. Effect of misoprostol in ethanol-induced liver injury
161. Misoprostol hepatoprotection against ischemia-reperfusion-induced liver injury in the rat
162. Novel applications of misoprostol
163. Hepatic ischemia-reperfusion injury modification during liver surgery in rats: Pre-treatment with nifedipine or misoprostol
164. Attenuation of ischemic liver injury by prostaglandin E1 analogue, misoprostol, and prostaglandin I2 analogue, OP-41483
165. Hepatic and gastric cytoprotective effects of long-term prostaglandin E1 administration in cirrhotic rats
166. Effect of misoprostol on the course of viral hepatitis B
167. One year follow-up of patients treated with misoprostol in acute phase of viral hepatitis B
168. Long-term administration of PGE1 increases liver fibrosis and collateral blood flow in bile-duct-ligated rats
169. Effects of four orally-administered analogues of prostaglandin E1 and E2 on glucose tolerance and on the secretion of pancreatic and gastrointestinal hormones in man
170. Protective effect of misoprostol, a synthetic prostaglandin E1 analog, on experimental pancreatitis induced by pancreatic duct ligation in rats
171. Protective effect of misoprostol, a synthetic prostaglandin E1 analog, on cerulein-induced acute pancreatitis in rats
172. Oral misoprostol for third stage of labor: A randomized placebo-controlled trial
173. Effects of misoprostol on pentylenetetrazoL-induced seizures in mice
174. Radioprotective effects of prostaglandins for chromosomal aberrations and cell killing in V79 Chinese hamster cells grown as spheroids in vitro and for mouse spermatogonial stem cells and bone marrow cells in vivo
175. Misoprostol-induced radioprotection of Syrian hamster embryo cells in utero from cell death and oncogenic transformation
176. Radioprotective effect of misoprostol on mouse spermatogonial stem cells
177. Misoprostol-induced radioprotection of oncogenic transformation
178. Misoprostol a potent cytotoxic and oncogenic radioprotector
179. In vivo and in vitro radioprotective effects of the prostaglandin E1 analogue misoprostol in DNA repair-proficient and deficient rodent celil systems
180. Differential radioprotective effects of misoprostoI in DNA repair-proficient and -deficient or radiosensitive cell systems
181. Radioprotection by misoprostol (PGE1 methyl analog) in combination with vitamin E, selenomethionine and WR-3689794
182. Behavioral radioprotective effects of misoprostol in adrenalectomized mice
183. The prostaglandin E1 analog, misoprostol, a normal tissue protector, does not protect four murine tumors in vivo from radiation injury
184. Prostaglandins protect against murine hair injury produced by ionizing radiation or doxorubicin
185. Synergistic protection of irradiated mice by a combination of iloprost and misoprostol
186. Misoprostol: New frontiers: Benefits beyond the gastrointestinal tract
187. Gastric mucosal damage in sepsis - Effects of pre-treatment with a synthetic prostaglandin E1 analogue
188. Prevention of gastric mucosal damage in live E. coli shock by pre-treatment with misoprostol
189. Misoprostol but not antacid prevents endotoxin-induced gastric mucosal injury: Role of tumor necrosis factor-alpha
190. The degree of bacterial translocation is a determinant factor for mortality after burn injury and is improved by prostaglandin analogs
191. Prostaglandin E1 analogues and enisoprost decrease microbial translocation and modulate the immune response
192. Prostaglandins and inhibitors of arachidonate metabolism suppress experimental allergic encephalomyelitis